CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

(LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better than ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Pfizer Q2 2025 earnings show 10% revenue growth, raised EPS guidance, strong R&D, and operational execution. Explore growth drivers and policy risks.

Most of its precision oncology products, including Lorbrena, Braftovi, Mektovi, and Talzenna, posted double-digit increases ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Bourla, who took over as CEO in 2019, has declined to say how long he intends to remain in his role at Pfizer. Developing a ...

Second-quarter adjusted earnings came in at 78 cents a share on revenue of $14.7 billion, beating expectations.

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Pfizer's stock surged following a report of stronger-than-expected earnings, driven by robust sales of COVID-19 products and ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...